BioNTech, UK collaborate on personalized mRNA cancer immunotherapy

Biontech company headquarters in Mainz, Germany

Alexander University

BioNTech (NASDAQ:BNTX) Signed a tentative agreement with the UK government to provide up to 10 thousand patients with personalized mRNA cancer immunotherapies by 2030.

German COVID vaccine maker aims to provide personalized cancer therapies to these patients


News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button